Inflammatory and Cholesterol Risk in the FOURIER Trial

In the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. It is not known whether th...

Full description

Bibliographic Details

Published in:	Circulation (New York, N.Y.) Vol. 138; no. 2; p. 131
Main Authors:	Bohula, Erin A, Giugliano, Robert P, Leiter, Lawrence A, Verma, Subodh, Park, Jeong-Gun, Sever, Peter S, Lira Pineda, Armando, Honarpour, Narimon, Wang, Huei, Murphy, Sabina A, Keech, Anthony, Pedersen, Terje R, Sabatine, Marc S
Format:	Journal Article
Language:	English
Published:	United States 10.07.2018
Subjects:	receptors, LDL cholesterol C-reactive protein inflammation evolocumab
ISSN:	1524-4539, 1524-4539
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!